| Old Articles: <Older 32061-32070 Newer> |
 |
The Motley Fool September 10, 2008 Toby Shute |
Look, Ma, No Emissions! Power producer Vattenfall AB has to be feeling pretty proud this week. The Swedish utility has turned out the world's first pilot plant to employ carbon capture and storage technology.  |
The Motley Fool September 10, 2008 Brian Orelli |
1 Drug Beats Another, but Who Will Care? Amylin Pharmaceuticals and Eli Lilly are fighting an uphill battle as they try to convince diabetics that the benefit from the two-needle-prick regimen of Byetta is worth the effort over popping a single pill.  |
The Motley Fool September 10, 2008 Rick Aristotle Munarriz |
Vote McCain! Vote Obama! Vote Bezos! A pair of biographies on the potential first ladies -- one on Michelle Obama, and another on Cindy McCain -- are being made available exclusively to Kindle readers over the next few days, months before the books hit retailers.  |
The Motley Fool September 10, 2008 Dan Caplinger |
High-Yield Stocks That Are Riskier Than You Think Preferred stocks pay higher dividends, but they aren't bulletproof.  |
The Motley Fool September 10, 2008 Brian Lawler |
A Pfizer Drug With a Cloudy Future The company offers another drug with mixed odds to the FDA.  |
The Motley Fool September 10, 2008 Rick Aristotle Munarriz |
Zune's 90% Solution A few days after the Microsoft announcement of new Zune features, let's see what the response has been.  |
The Motley Fool September 10, 2008 Chuck Saletta |
Retire With a Real Million Bucks How can you invest your savings to earn returns that get you to that magic number?  |
The Motley Fool September 10, 2008 Rick Aristotle Munarriz |
Should Fools Believe in Sirius? Shares of Sirius XM Radio hit a five-year low, but investors should be patient with the newly-merged company.  |
The Motley Fool September 10, 2008 Rich Smith |
iRobot: All Gas, No Brakes Two significant new announcements from iRobot.  |
The Motley Fool September 10, 2008 Brian Orelli |
Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.  |
| <Older 32061-32070 Newer> Return to current articles. |